270 related articles for article (PubMed ID: 33328701)
1. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.
Chai NX; Chapiro J
Semin Intervent Radiol; 2020 Dec; 37(5):456-465. PubMed ID: 33328701
[TBL] [Abstract][Full Text] [Related]
2. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
[TBL] [Abstract][Full Text] [Related]
3. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
4. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
5. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.
Razi M; Safiullah S; Gu J; He X; Razi M; Kong J
J Interv Med; 2022 Feb; 5(1):10-14. PubMed ID: 35586278
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
Manjunatha N; Ganduri V; Rajasekaran K; Duraiyarasan S; Adefuye M
Cureus; 2022 Aug; 14(8):e28439. PubMed ID: 36176866
[TBL] [Abstract][Full Text] [Related]
7. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
9. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
11. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
12. Conventional
Song JE; Kim DY
World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
[TBL] [Abstract][Full Text] [Related]
13. Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.
Narayanan A; Garza-Berlanga A; Lopera J
Ann Palliat Med; 2023 Nov; 12(6):1244-1259. PubMed ID: 37574584
[TBL] [Abstract][Full Text] [Related]
14. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
Li H; Liang C; Kuang D; Huang G; Zhang M; Chen P; Zheng Q; Xu W; Ren J; Han X; Duan X
Cancer Biol Ther; 2023 Dec; 24(1):2166335. PubMed ID: 36751709
[TBL] [Abstract][Full Text] [Related]
15. Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.
Mouli SK; Goff LW
Curr Treat Options Oncol; 2017 Oct; 18(11):67. PubMed ID: 29080006
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study.
Morishita A; Tani J; Nomura T; Takuma K; Nakahara M; Oura K; Tadokoro T; Fujita K; Shi T; Yamana H; Matsui T; Takata T; Sanomura T; Nishiyama Y; Himoto T; Tomonari T; Moriya A; Senoo T; Takaguchi K; Masaki T
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572832
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
20. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]